Asia
Update: Telix Pharmaceuticals Posts Higher Q2 Revenue; Shares Rise 3%
(Updates to add stock movement in the last paragraph)Telix Pharmaceuticals (ASX:TLX) reported second-quarter revenue rose 21% to $247 million due to strong sale of precision medicine category, according to a Tuesday filing with the Australian bourse.The company expects fiscal 2026 revenue and other income to be more than $1 billion, with income tracking in line with the upper end of the outlook of $950 million to $970 million.It increased its fiscal 2026 research and development expenditure outlook to $230 million to $270 million from the prior range of $200 million to$240 million.The company's shares rose 3% in recent Tuesday trade.
ASX:TLX
